603998 方盛制药
已收盘 08-03 15:00:00
资讯
新帖
简况
方盛制药(603998)披露公司产品拟中选第十二批国家组织药品集中带量采购,8月3日股价上涨1.06%
证券之星 · 22:37
方盛制药(603998)披露公司产品拟中选第十二批国家组织药品集中带量采购,8月3日股价上涨1.06%
方盛制药(603998)披露关于签订项目回购协议的进展公告,7月28日股价下跌0.11%
证券之星 · 07-28
方盛制药(603998)披露关于签订项目回购协议的进展公告,7月28日股价下跌0.11%
方盛制药(603998)披露拟退出并购基金暨关联交易议案,7月15日股价上涨2.94%
证券之星 · 07-15
方盛制药(603998)披露拟退出并购基金暨关联交易议案,7月15日股价上涨2.94%
方盛制药:公司积极关注回报投资者,累计实施分红19次
证券日报网 · 07-15
方盛制药:公司积极关注回报投资者,累计实施分红19次
方盛制药:小儿荆杏止咳颗粒的疗效明显优于安慰剂
证券日报网 · 07-15
方盛制药:小儿荆杏止咳颗粒的疗效明显优于安慰剂
方盛制药(603998)披露公司《药品生产许可证》变更公告,7月9日股价下跌2.75%
证券之星 · 07-09
方盛制药(603998)披露公司《药品生产许可证》变更公告,7月9日股价下跌2.75%
方盛制药(603998)披露拟退出长沙同系方盛合伙企业财产份额事项,7月8日股价上涨1.83%
证券之星 · 07-08
方盛制药(603998)披露拟退出长沙同系方盛合伙企业财产份额事项,7月8日股价上涨1.83%
股市必读:方盛制药(603998)7月3日披露最新机构调研信息
证券之星 · 07-06
股市必读:方盛制药(603998)7月3日披露最新机构调研信息
每周股票复盘:方盛制药(603998)拟退伙同系方盛获益约1520万
证券之星 · 07-05
每周股票复盘:方盛制药(603998)拟退伙同系方盛获益约1520万
方盛制药:7月1日接受机构调研,浙商证券、国泰基金等多家机构参与
证券之星 · 07-03
方盛制药:7月1日接受机构调研,浙商证券、国泰基金等多家机构参与
股市必读:方盛制药(603998)7月1日董秘有最新回复
证券之星 · 07-02
股市必读:方盛制药(603998)7月1日董秘有最新回复
方盛制药:方盛堂互联网医院暂未实际经营
证券之星 · 07-01
方盛制药:方盛堂互联网医院暂未实际经营
方盛制药:公司以制药业务为主
证券之星 · 07-01
方盛制药:公司以制药业务为主
方盛制药:公司已将市值管理纳入部分高级管理人员绩效考核指标
证券之星 · 07-01
方盛制药:公司已将市值管理纳入部分高级管理人员绩效考核指标
每周股票复盘:方盛制药(603998)收回并购基金全部出资1亿元
证券之星 · 06-28
每周股票复盘:方盛制药(603998)收回并购基金全部出资1亿元
方盛制药(603998)披露公司参与投资设立的并购基金对外出售投资项目部分股份的进展公告,6月25日股价下跌2.54%
证券之星 · 06-25
方盛制药(603998)披露公司参与投资设立的并购基金对外出售投资项目部分股份的进展公告,6月25日股价下跌2.54%
方盛制药(603998)披露转让控股子公司部分股权暨引进战略投资者进展公告,6月22日股价下跌1.39%
证券之星 · 06-22
方盛制药(603998)披露转让控股子公司部分股权暨引进战略投资者进展公告,6月22日股价下跌1.39%
方盛制药最新公告:拟向全资子公司增资1.55亿元
证券之星 · 06-08
方盛制药最新公告:拟向全资子公司增资1.55亿元
每周股票复盘:方盛制药(603998)变更受让药品品种
证券之星 · 06-07
每周股票复盘:方盛制药(603998)变更受让药品品种
每周股票复盘:XD方盛制(603998)方盛制药每股派现0.15元(含税)
证券之星 · 05-31
每周股票复盘:XD方盛制(603998)方盛制药每股派现0.15元(含税)
加载更多
公司概况
公司名称:
湖南方盛制药股份有限公司
所属行业:
医药制造业
上市日期:
2014-12-05
主营业务:
湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是血塞通分散片、血塞通片、藤黄健骨片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊、蒲地蓝消炎片、小儿荆杏止咳颗粒、依折麦布片、玄七健骨片、强力枇杷膏(蜜炼)、强力枇杷露。近三年(2023-2025年)公司先后获得国家绿色工厂、中成药百强工业、湖南省智能制造标杆车间、湖南省消费品工业“三品”标杆企业、湖南省“高新技术企业税收贡献百强”等多项荣誉称号。
发行价格:
14.85
{"stockData":{"symbol":"603998","market":"SH","secType":"STK","nameCN":"方盛制药","latestPrice":9.56,"timestamp":1785740400000,"preClose":9.46,"halted":0,"volume":6222500,"delay":0,"changeRate":0.0106,"floatShares":438999999,"shares":438999999,"eps":0.6981,"marketStatus":"已收盘","change":0.1,"latestTime":"08-03 15:00:00","open":9.5,"high":9.59,"low":9.46,"amount":59355600,"amplitude":0.0137,"askPrice":9.56,"askSize":5,"bidPrice":9.55,"bidSize":302,"shortable":0,"etf":0,"ttmEps":0.6981,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785807000000},"marketStatusCode":5,"adr":0,"adjPreClose":9.46,"symbolType":"stock","openAndCloseTimeList":[[1785720600000,1785727800000],[1785733200000,1785740400000]],"highLimit":10.41,"lowLimit":8.51,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":439081360,"isCdr":false,"pbRate":2.42,"roa":"--","peRate":13.694313,"roe":"5.16%","epsLYR":0.7,"committee":-0.289264,"marketValue":4198000000,"turnoverRate":0.0142,"status":0,"floatMarketCap":4198000000},"requestUrl":"/m/hq/s/603998/","defaultTab":"news","newsList":[{"id":"2656377420","title":"方盛制药(603998)披露公司产品拟中选第十二批国家组织药品集中带量采购,8月3日股价上涨1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656377420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656377420?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:37","pubTimestamp":1785767834,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘,方盛制药报收于9.56元,较前一交易日上涨1.06%,最新总市值为41.98亿元。公告显示,公司参加第十二批国家组织药品集中带量采购,产品吲哚布芬片及全资子公司广东方盛健盟药业有限公司产品比索洛尔氨氯地平片拟中选。吲哚布芬片适用于缺血性心脑血管疾病等,比索洛尔氨氯地平片用于高血压替代治疗。采购周期至2029年12月31日,采购协议每年一签或一次性签约。拟中选结果尚在公示期,最终以国家联采办发布数据为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654883351","title":"方盛制药(603998)披露关于签订项目回购协议的进展公告,7月28日股价下跌0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654883351","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654883351?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:25","pubTimestamp":1785248717,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘,方盛制药报收于9.13元,较前一交易日下跌0.11%,最新总市值为40.09亿元。近日,方盛制药发布《关于签订项目回购协议的进展公告》。公告显示,2024年8月27日,公司与正帆建设、金帆建设、滕王阁药业、南昌经开控股签署《项目回购协议》,委托正帆建设代建南昌基地项目,预计回购价款不超过2亿元。目前公司及滕王阁药业已完成审批,其他方尚在履行审批程序。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651850461","title":"方盛制药(603998)披露拟退出并购基金暨关联交易议案,7月15日股价上涨2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651850461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651850461?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:16","pubTimestamp":1784124980,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘,方盛制药报收于10.17元,较前一交易日上涨2.94%,最新总市值为44.65亿元。近日,方盛制药发布2026年第一次临时股东会决议公告。公告显示,公司于2026年7月15日召开2026年第一次临时股东会,审议通过了《关于公司拟退出并购基金暨关联交易的议案》。出席会议股东共240人,代表有表决权股份36,336,821股,占公司总股本的13.2855%。议案获同意票36,192,920股,占比99.6039%,反对和弃权票分别为79,001股和64,900股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651461820","title":"方盛制药:公司积极关注回报投资者,累计实施分红19次","url":"https://stock-news.laohu8.com/highlight/detail?id=2651461820","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651461820?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:38","pubTimestamp":1784122680,"startTime":"0","endTime":"0","summary":"证券日报网7月15日讯,方盛制药在接受调研者提问时表示,公司积极关注回报投资者,累计实施分红19次,分红总额约8.21亿元 。为切实增强投资者获得感,自2020年开始,公司率先推行一年多次分红机制,至今已完成5次中期分红及2次特别分红,积极让股东分享发展红利。2025年,公司全年每股派现0.45元(含税),合计分红金额197586612元,占2025年合并报表中归属于上市公司普通股股东的净利润的64.49%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-15/doc-inihxaew4695655.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-15/doc-inihxaew4695655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VIG","BK4588","603998","BK0060","BK0239","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651461655","title":"方盛制药:小儿荆杏止咳颗粒的疗效明显优于安慰剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2651461655","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651461655?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:35","pubTimestamp":1784122500,"startTime":"0","endTime":"0","summary":"证券日报网7月15日讯 ,方盛制药在接受调研者提问时表示,2026年4月28日,公司研发的小儿荆杏止咳颗粒取得了成人急性气管-支气管炎 的III期临床试验总结报告。试验数据显示,小儿荆杏止咳颗粒的疗效明显优于安慰剂,已达到预期研究主要终点。目前,公司已向国家药品监督管理局提出成人适用症相关事项补充申请并收到《受理通知书》,后续药品研发注册如有新的进展,公司将严格按照有关法律法规的规定及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-15/doc-inihxaeu7918897.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-15/doc-inihxaeu7918897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650797895","title":"方盛制药(603998)披露公司《药品生产许可证》变更公告,7月9日股价下跌2.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650797895","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650797895?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:39","pubTimestamp":1783607951,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘,方盛制药报收于9.18元,较前一交易日下跌2.75%,最新总市值为40.31亿元。近日,方盛制药发布关于公司《药品生产许可证》变更的公告。公告显示,湖南方盛制药股份有限公司完成了《药品生产许可证》的变更登记,并取得湖南省药品监督管理局核发的新证。变更后的许可证有效期至2030年10月16日。本次变更不会对公司现有生产结构和本期业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649994936","title":"方盛制药(603998)披露拟退出长沙同系方盛合伙企业财产份额事项,7月8日股价上涨1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649994936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649994936?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:32","pubTimestamp":1783521138,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,方盛制药报收于9.44元,较前一交易日上涨1.83%,最新总市值为41.45亿元。近日,方盛制药披露《2026年第一次临时股东会会议资料》,拟退出其持有的长沙同系方盛健康产业投资合伙企业1亿份财产份额,该事项构成关联交易。本次退伙有利于公司聚焦主业,减少管理成本。退伙后公司预计将确认投资收益约1,520.89万元,具体以审计结果为准。本事项已经董事会审议通过,尚需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649619782","title":"股市必读:方盛制药(603998)7月3日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2649619782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649619782?lang=zh_cn&edition=full","pubTime":"2026-07-06 04:53","pubTimestamp":1783284787,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,方盛制药报收于9.73元,上涨3.62%,换手率2.34%,成交量10.29万手,成交额9929.76万元。机构调研要点:公司拟退伙长沙同系方盛健康产业投资合伙企业,退出其持有的21.39%财产份额,该事项已获董事会审议通过,尚待临时股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600001716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649692759","title":"每周股票复盘:方盛制药(603998)拟退伙同系方盛获益约1520万","url":"https://stock-news.laohu8.com/highlight/detail?id=2649692759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649692759?lang=zh_cn&edition=full","pubTime":"2026-07-05 04:31","pubTimestamp":1783197069,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,方盛制药报收于9.73元,较上周的8.85元上涨9.94%。本周,方盛制药7月3日盘中最高价报9.74元。本周关注点来自公司公告汇总:方盛制药拟退出并购基金同系方盛,预计确认投资收益约1,520.89万元。方盛制药将于2026年7月15日召开2026年第一次临时股东会,采用现场与网络投票结合方式,现场会议于当日15时30分在公司会议室举行,网络投票通过上交所系统进行。同系方盛为公司与关联方汇智新元等共同设立,本次退伙构成关联交易。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648668027","title":"方盛制药:7月1日接受机构调研,浙商证券、国泰基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648668027?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:32","pubTimestamp":1783074747,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年7月3日方盛制药发布公告称公司于2026年7月1日接受机构调研,浙商证券、国泰基金、国中长城资管、开源证券参与。方盛制药2026年一季报显示,一季度公司主营收入4.63亿元,同比上升10.69%;归母净利润8839.17万元,同比上升0.15%;扣非净利润8583.76万元,同比上升21.19%;负债率39.93%,投资收益41.53万元,财务费用189.36万元,毛利率75.33%。该股最近90天内共有5家机构给出评级,买入评级5家;过去90天内机构目标均价为16.39。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300037588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","603998","BK0239","601878","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648526354","title":"股市必读:方盛制药(603998)7月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648526354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648526354?lang=zh_cn&edition=full","pubTime":"2026-07-02 04:09","pubTimestamp":1782936551,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘,方盛制药报收于9.2元,上涨1.88%,换手率2.21%,成交量9.71万手,成交额8793.09万元。董秘最新回复投资者: 董秘您好,公司股价已连续 4 个月持续下跌,基本面无重大利空。公司董事会、管理层高度重视市值维护,已将市值管理纳入部分高级管理人员绩效考核指标。方盛堂互联网医院暂未实际经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200001934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648851677","title":"方盛制药:方盛堂互联网医院暂未实际经营","url":"https://stock-news.laohu8.com/highlight/detail?id=2648851677","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648851677?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:03","pubTimestamp":1782896598,"startTime":"0","endTime":"0","summary":"证券之星消息,方盛制药(603998)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:公司多元化发展非常好!请问贵公司的互联网医院什么时候能建成?什么时候能AI看病?方盛制药回复:尊敬的投资者,您好!方盛堂互联网医院暂未实际经营。感谢您的关注,敬请注意投资风险。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648451677","title":"方盛制药:公司以制药业务为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2648451677","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648451677?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:03","pubTimestamp":1782896596,"startTime":"0","endTime":"0","summary":"证券之星消息,方盛制药07月01日在投资者关系平台上答复投资者关心的问题。公司以制药业务为主,主要在销产品为养血祛风止痛颗粒、藤黄健骨片、小儿荆杏止咳颗粒、强力枇杷膏(蜜炼)、依折麦布片、玄七健骨片、血塞通分散片/片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516727","title":"方盛制药:公司已将市值管理纳入部分高级管理人员绩效考核指标","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516727?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:00","pubTimestamp":1782896442,"startTime":"0","endTime":"0","summary":"证券之星消息,方盛制药07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,公司股价已连续 4 个月持续下跌,基本面无重大利空。公司董事会、管理层高度重视市值维护,已将市值管理纳入部分高级管理人员绩效考核指标。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646315242","title":"每周股票复盘:方盛制药(603998)收回并购基金全部出资1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646315242","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646315242?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:43","pubTimestamp":1782589389,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,方盛制药报收于8.85元,较上周的9.35元下跌5.35%。本周,方盛制药6月24日盘中最高价报9.7元。方盛制药关于公司参与投资设立的并购基金对外出售投资项目部分股份的进展公告2026年6月25日,湖南方盛制药股份有限公司收到同系方盛转来款项2,085.46万元,公司对同系方盛的实缴出资1亿元已全部收回。公司后续将就同系方盛的清算及份额退出进行协商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646092048","title":"方盛制药(603998)披露公司参与投资设立的并购基金对外出售投资项目部分股份的进展公告,6月25日股价下跌2.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646092048","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646092048?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:42","pubTimestamp":1782398541,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘,方盛制药报收于9.22元,较前一交易日下跌2.54%,最新总市值为40.48亿元。近日,方盛制药发布《关于公司参与投资设立的并购基金对外出售投资项目部分股份的进展公告》。公告显示,2026年6月25日,湖南方盛制药股份有限公司收到同系方盛转来款项2,085.46万元,公司对同系方盛的实缴出资1亿元已全部收回。此前,湖南珂信于2026年6月8日向同系方盛支付第二期股权回购款。公司后续将就同系方盛的清算及份额退出进行协商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073959","title":"方盛制药(603998)披露转让控股子公司部分股权暨引进战略投资者进展公告,6月22日股价下跌1.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073959","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645073959?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:32","pubTimestamp":1782138737,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘,方盛制药报收于9.22元,较前一交易日下跌1.39%,最新总市值为40.48亿元。近日,湖南方盛制药股份有限公司发布关于转让控股子公司部分股权暨引进战略投资者的进展公告。根据《经修订和重述的和解和框架协议》,佰骏医疗应自2025年起每季度偿还不少于600万元,首次还款日为2025年3月21日。截至公告日,佰骏医疗已累计偿还12,000万元,尚余4,593.35万元未还。公司提示仍存在佰骏医疗无法按时足额还款的风险,并将持续关注进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200039005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641945483","title":"方盛制药最新公告:拟向全资子公司增资1.55亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641945483","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641945483?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:01","pubTimestamp":1780912871,"startTime":"0","endTime":"0","summary":"方盛制药(603998.SH)公告称,全资子公司方盛康华因建设国际工业园一期、二期项目投入大量资金,前期主要依靠向母公司借款。现为增强其资金实力、优化负债结构,公司拟使用自有资金对方盛康华增资1.55亿元。本次增资完成后,方盛康华仍为公司全资子公司。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800024887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127445","title":"每周股票复盘:方盛制药(603998)变更受让药品品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127445?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:50","pubTimestamp":1780771819,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘,方盛制药报收于9.68元,较上周的9.9元下跌2.22%。本周,方盛制药6月1日盘中最高价报10.21元。方盛制药当前最新总市值42.5亿元,在中药板块市值排名47/66,在两市A股市值排名3690/5206。本周关注点公司公告汇总:方盛制药变更受让药品品种,调整三个拟上市中成药品种。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639266604","title":"每周股票复盘:XD方盛制(603998)方盛制药每股派现0.15元(含税)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639266604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639266604?lang=zh_cn&edition=full","pubTime":"2026-05-31 04:01","pubTimestamp":1780171299,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,XD方盛制报收于9.9元,较上周的10.26元下跌3.51%。本周,XD方盛制5月25日盘中最高价报10.32元。本周关注点公司公告汇总:方盛制药每股派发现金红利0.15元(含税),股权登记日为2026年5月28日。本次利润分配以公司总股本439,081,360股为基数,共计派发现金红利65,862,204元。分派对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785772282343,"stockEarnings":[{"period":"1week","weight":0.0558},{"period":"1month","weight":0.0283},{"period":"3month","weight":-0.1259},{"period":"6month","weight":-0.186},{"period":"1year","weight":-0.1328},{"period":"ytd","weight":-0.1345}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":-0.0681},{"period":"3month","weight":-0.0681},{"period":"6month","weight":-0.0694},{"period":"1year","weight":0.0725},{"period":"ytd","weight":-0.0344}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南方盛制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24973人(较上一季度减少10.49%)","perCapita":"17582股","listingDate":"2014-12-05","address":"湖南省长沙市岳麓区高新区麓松路789号","registeredCapital":"43908万元","survey":" 湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是血塞通分散片、血塞通片、藤黄健骨片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊、蒲地蓝消炎片、小儿荆杏止咳颗粒、依折麦布片、玄七健骨片、强力枇杷膏(蜜炼)、强力枇杷露。近三年(2023-2025年)公司先后获得国家绿色工厂、中成药百强工业、湖南省智能制造标杆车间、湖南省消费品工业“三品”标杆企业、湖南省“高新技术企业税收贡献百强”等多项荣誉称号。","listedPrice":14.85},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"方盛制药,603998,方盛制药股票,方盛制药股票老虎,方盛制药股票老虎国际,方盛制药行情,方盛制药股票行情,方盛制药股价,方盛制药股市,方盛制药股票价格,方盛制药股票交易,方盛制药股票购买,方盛制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}